Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus

Khattar, Sunil K.; Palaniyandi, Senthilkumar; Samal, Sweety; LaBranche, Celia C.; Montefiori, David C.; Zhu, Xiaoping; Samal, Siba K.

doi:10.4161/21645515.2014.987006

Cited by 6 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ideal HIV vaccine should not only stimulate a long-lasting neutralizing antibody response, it should also elicit strong cell-mediated immunity, particularly a CD8 + response, which is believed to play a crucial role in virus clearance [127]. With the gag and pol proteins being the most important elicitors of robust immune responses against HIV [128], attempts have been made to construct a recombinant vectored vaccine expressing these proteins. In one study, genetically engineered NDV expressing HIV gp140 or gp160 have been shown to induce a strong anti-HIV humoral immune response following parenteral or intranasal administration in mice [61].…”

Section: Engineered Ndv As a Vaccine Vector In Manmentioning

confidence: 99%

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

Bello

Yusoff

Ideris

et al. 2020

Viruses

View full text Add to dashboard Cite

Many traditional vaccines have proven to be incapable of controlling newly emerging infectious diseases. They have also achieved limited success in the fight against a variety of human cancers. Thus, innovative vaccine strategies are highly needed to overcome the global burden of these diseases. Advances in molecular biology and reverse genetics have completely restructured the concept of vaccinology, leading to the emergence of state-of-the-art technologies for vaccine design, development and delivery. Among these modern vaccine technologies are the recombinant viral vectored vaccines, which are known for their incredible specificity in antigen delivery as well as the induction of robust immune responses in the vaccinated hosts. Although a number of viruses have been used as vaccine vectors, genetically engineered Newcastle disease virus (NDV) possesses some useful attributes that make it a preferable candidate for vectoring vaccine antigens. Here, we review the molecular biology of NDV and discuss the reverse genetics approaches used to engineer the virus into an efficient vaccine vector. We then discuss the prospects of the engineered virus as an efficient vehicle of vaccines against cancer and several infectious diseases of man and animals.

show abstract

Section: Engineered Ndv As a Vaccine Vector In Manmentioning

confidence: 99%

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

Bello

Yusoff

Ideris

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…There is no preexisting immunity to NDV in humans. NDV infects via the intranasal and oral routes and induces both mucosal and systemic immune responses (9)(10)(11)(12)(13)(14)(15)(16)(17). Previously, we demonstrated the potential of NDV as a vaccine vector for HIV-1 (14)(15)(16)(17).…”

mentioning

confidence: 99%

Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins

Khattar

DeVico

LaBranche

et al. 2016

J Virol

View full text Add to dashboard Cite

dNewcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alone or with monomeric BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelope (Env)-specific humoral and mucosal immune responses. We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger serum and mucosal Th-1-biased IgG responses and neutralizing antibody responses than NDV-only immunizations. Additionally, these responses were higher after the gp120 than after the SOSIP gp140 protein boost. It is believed that an effective vaccine against HIV-1 should induce potent systemic and mucosal immune responses. Therefore, the use of live-virus vectored vaccines capable of replicating at mucosal surface has become very attractive. To induce robust antibody (Ab) responses, several of these vectored vaccines are being evaluated either alone or in several prime-boost combinations using different forms of HIV envelope (Env) protein (1-4). It has been reported that a viral vector prime and protein boost regiment could elicit protective immunity to HIV-1 in nonhuman primates (4-7) and, recently, in humans in an RV-144 vaccine trial (8). Among the different viral vector systems under evaluation for HIV, Newcastle disease virus (NDV), an avian paramyxovirus, has the characteristics desired for an HIV-1 vaccine. There is no preexisting immunity to NDV in humans. NDV infects via the intranasal and oral routes and induces both mucosal and systemic immune responses (9-17). Previously, we demonstrated the potential of NDV as a vaccine vector for HIV-1 (14-17). However, the concept of an NDV vector prime followed by Env protein boost to increase immune responses to HIV has never been evaluated previously.In order to identify an improved vaccination regimen that elicits a higher level of anti-HIV humoral as well as mucosal immune responses, an avirulent recombinant NDV (rNDV) strain, LaSota, expressing gp160 of HIV-1 strain BaL.1 was used as a prime followed by a boost with purified monomeric gp120 and trimeric SOSIP gp140 proteins in this study. The construction and characterization of rNDV expressing gp160 (rNDV-gp160) were described before (16). Briefly, the gp160 protein expressed by rNDV was detected on infected cell surfaces and was also incorporated into the NDV virion. Further, gp160 present in infected cells and in the virion formed oligomers which were recognized by conformationally dependent monoclonal Abs (MAbs). The BaL gp120 and SOSIP gp140 proteins (18) were produced as described previously (19). The BaL SOSIP gp140 protein has been characterized by Dey et al. (19), and they demonstrated that BaL SOSIP gp140, expressed in HEK 293 cells, was a mixture of monomers, dimers, and trimers. Guinea pigs were used to evaluate the humoral and mucosal immune responses induced by this vaccine regimen. Female Hartley guinea pigs obtained from Charles River Laboratories were assigned to four groups (n ϭ 3/group) as shown in Fig. 1. Each animal in all the groups recei...

show abstract

“…Additionally, rNDV/gp140S induced greater CD4 + and CD8 + T-cell response in mice [91]. The combination of multiple HIV antigens in rNDV vaccine vector to broaden antiviral immune responses showed that inclusion of Gag with gp160, gp140S and gp140L enhanced the level of Env-specific IFN-γ-producing CD8 + T cells in mice, and inclusion of Gag with gp160 and gp140L also resulted in increased Env-specific CD4 + T cells, indicating lack of antigen interference in a vaccine containing rNDVs expressing Env and Gag proteins [92]. Taken together, these data illustrate that rNDV expressing HIV-1 gag or Env protein is a promising vaccine candidate to elicit potent mucosal, humoral and cellular immune responses against HIV-1 infection.…”

Section: Rndv-vectored Vaccine Against Human Infectious Diseasesmentioning

confidence: 95%

“…Additionally, NDV shares only a low level of amino acid sequence identity with human viruses and is distinct antigenically, suggesting that the human population would be susceptible to vaccination with rNDV-based vectors [71]. Recent advances using reverse genetics have indeed provided a means of generating rNDV with potent vaccine vector against human infectious diseases [86][87][88][89][90][91][92][95][96][97][98][99][100]. Although studies with animal models showed that NDV expressing protective antigens of HIV, human respiratory syncytial virus, Nipah virus or SIV were immunogenic and induced protection against challenge, however, mice and guinea pigs are not good models for evaluating a host range-restricted vector against human pathogens, because their permissiveness to both the vector and the pathogen probably do not accurately reflect that of the human due to the phylogenetic distance.…”

Section: Conclusion and Future Perspectivementioning

confidence: 98%

“…Intranasal Mucosal, humoral and cellular [92] SARS-CoV S African green monkeys Intranasal and intratracheal Humoral [93] EBOV GP Rhesus monkeys Intranasal and intratracheal Humoral [95] HPIV3 HN African green monkeys Intranasal and intratracheal Humoral [63] EV 71 VP1 Rabbits Intramuscular Humoral [96] HRSV F Mice Intranasal Cellular [97] NiV G Mice and pigs Intramuscular Humoral [98] F Mice Intramuscular Humoral and cellular RVFV Gn or Gc Mice Intramuscular Humoral [99] NoV VP1 Mice Intranasal Cellular www.futuremedicine.com…”

Section: Micementioning

confidence: 99%

See 1 more Smart Citation

Recombinant Newcastle Disease Virus-Vectored Vaccines Against Human and Animal Infectious Diseases

Duan

et al. 2015

Future Microbiol.

View full text Add to dashboard Cite

Recent advances in recombinant genetic engineering techniques have brought forward a leap in designing new vaccines in modern medicine. One attractive strategy is the application of reverse genetics technology to make recombinant Newcastle disease virus (rNDV) deliver protective antigens of pathogens. In recent years, numerous studies have demonstrated that rNDV-vectored vaccines can induce quicker and better humoral and mucosal immune responses than conventional vaccines and are protective against pathogen challenges. With deeper understanding of NDV molecular biology, it is feasible to develop gene-modified rNDV vaccines accompanied by good safety, high efficacy, low toxicity and better immunogenicity. This review summarizes the development of reverse genetics technology in using NDV as a promising vaccine vector to design new vaccines for human and animal use.

show abstract

Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus

Cited by 6 publications

References 47 publications

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins

Recombinant Newcastle Disease Virus-Vectored Vaccines Against Human and Animal Infectious Diseases

Contact Info

Product

Resources

About